Exploring novel genomic biomarkers for response and survival after neoadjuvant chemotherapy and radical cystectomy of muscle-invasive bladder cancer
Background: Neoadjuvant cisplatin-based combination chemotherapy (NAC) is standard perioperative treatment of patients with muscle-invasive urothelial bladder cancer (MIBC); however, about half of the patients experience recurrence of the disease. Biomarkers for response and survival represent an unmet medical need. We used tumor specimens from transurethral resections of the bladder to explore ge
